Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Tech Gastrointest Endosc. 2017 Jan 25;19(1):52–60. doi: 10.1016/j.tgie.2017.01.003

Table 4.

Overview of FDA-Approved Bariatric Endoscopic Procedures (21)

Name Mechanism Total body weight
loss %		 Adverse effects*
Orbera intragastric
balloon		 Gastric occupying
space; delays gastric
emptying		 11.3%a,(43) Nausea, fullness, 1%
migration
Re-shape intragastric
balloon		 7.9%b,(42) Nausea, fullness
AspireAssist aspiration
therapy		 Facilitates partial
removal of gastric
contents		 12.1(44) Less than 0.5% risk of
peritonitis, ulceration
and abdominal pain.
Endoscopic sleeve
gastroplasty		 Restrictive procedure;
delays gastric emptying		 20%c,(45) Nausea, pain, reflux,
risk of bleeding
a

Intragastric balloon removed at 6 months and reported: TBWL at 12 months;

b

Intragastric balloon removed at 6 months and reported: TBWL at 9 months;

c

Intragastric balloon removed at 6 months and reported: TBWL at 18 months